Overview
- The FDA this week cleared an Expanded Access Protocol for Intermountain Health to provide daraxonrasib at 10 hospitals in Utah, Colorado and Montana, and Intermountain says nine local patients are approved and awaiting the first shipments.
- Daraxonrasib is an oral targeted therapy that blocks mutant KRAS signals; a roughly 500‑patient phase 3 trial presented at ASCO found median survival rose from 6.7 months to 13.2 months for second‑line metastatic patients.
- The drug remains investigational and is not a cure; care teams will select patients case by case and monitor for common toxicities such as rash, diarrhea and mouth sores.
- Access through the program requires a physician request and manufacturer shipments, and wider patient access depends on the FDA review of a formal approval application submitted on July 22.
- Pancreatic cancer causes tens of thousands of U.S. deaths each year and is often found late, so early community access to a KRAS‑directed pill could change care for patients who exhausted standard chemotherapy and could prompt wider adoption if regulators authorize the drug.